Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2101-2103

  Harris, Randall E ^a,c   Alshafie, Galal A ^a   Abou Issa, Hussein ^a   Seibert, Karen ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CARCINOGENESIS; CHEMOPROPHYLAXIS; DIETARY INTAKE; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; IBUPROFEN; ISOENZYMES; MAMMARY NEOPLASMS, ANIMAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 0034655238     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Singletary, E. S., Bevers, T., Dempsey, P., Farrar, W. B., Garber, J., Harris, R. E., Helvie, M., Jacobs, M., Pass, H., Patterson-Smith, M. L., Tarantolo, S., and Venta, L. A. Screening for and evaluation of suspicious breast lesions. Oncology (Basel), 12: 89-138, 1998.
2. Harris, R. E., Kasbari, S., and Farrar, W. B. Prospective study of nonsteroidal drugs and breast cancer. Oncol. Rep., 6: 71-73, 1999.
3. Harris, R. E., Namboodiri, K. K., and Farrar, W. B. Epidemiologic study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol. Rep., 2: 591-592, 1995.
4. Harris, R. E., Namboodiri, K. K., and Farrar, W. B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology, 7: 203-205, 1996.
5. Lee, P. P., and Ip, M. M. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukotrienes Essent. Fatty Acids, 45: 21-31, 1992.
6. McCormick, D. L., Madigan, M. J., and Moon, R. C. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res., 45: 1803-1808, 1985.
7. Joarder, F. S., Abou-Issa, H., Robertson, F. M., Parrett, M. L., Alshafie, G. A., and Harris, R. E. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female Sprague-Dawley rats. Oncol. Rep., 4: 1271-1273, 1997.
8. Robertson, F. M., Parrett, M. L., Joarder, F. S., Ross, M., Abou-Issa, H. M., Alshafie, G., and Harris, R. E. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett., 122: 165-175, 1998.
9. Alshafie, G. A., Harris, R. E., Abou-Issa, H., Robertson, F. M., Parrett, M. L., and Ross, M. Chemopreventive effects of ibuprofen and 4-HPR in the DMBA rat mammary tumor model. Anticancer Res., 19: 1-6, 1999.
10. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231: 232-235, 1971.
11. Herschman, H. R. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev., 13: 241-256, 1994.
12. Parrett, M. L., Harris, R. E., Joarder, F. S., Ross, M. S., Clausen, K. P., and Robertson, F. M. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol., 10: 503-507, 1997.
13. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology, 137: 5739-5742, 1996.
14. Brueggemeier, R. W., Quinn, A. L., Parrett, M. L., Joarder, F. S., Harris, R. E., and Robertson, F. M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett., 140: 27-35, 1999.
15. Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., and Vane, J. R. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA, 90: 11693-11697, 1994.
16. Elston, R. C., and Johnson, W. D. Essentials of Biostatistics, 2nd ed. Philadelphia: F. A. Davis Company, 1994.
17. Abou-Issa, H., Webb, T. E., Minton, J. P., and Moeschberger, M. Chemotherapeutic evaluation of glucurate:N-(-4-hydroxyphenyl)-retinamide combination in the rat mammary tumor model. J. Natl. Cancer Inst., 81: 1820-1823, 1998.
18. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.
19. Reddy, B. S., Tokumo, K., Kulkarni, N., Aligia, C., and Kelloff, G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis (Lond.). 13: 1019-1023, 1992.
20. Harris, R. E., Robertson, F. M., Abou-Issa, H. M., Farrar, W. B., and Brueggemeier, R. Genetic induction and up-regulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med. Hypotheses, 52: 292-293, 1999.
21. Shou, M., Korzekwa, K. R., Krausz, K. W., Buters, J. T., Grogan, J., Goldfarb, I., Hardwick, J. P., Gonzalez, F. L., and Gelboin, H. V. Specificity of cDNA-expressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7,12-dimethylbenz(a)anthracene. Mol. Carcinogen., 17: 241-249, 1996.